

Anti-Inflammatory Reliever (AIR) Therapy

BUDESONIDE + FORMOTEROL

Symbicort® **DuoResp Spiromax®**




100/6 200/6 200/6

Turbuhaler® Dry powder inhaler

Short-Acting Beta2 Agonists (SABA)

SALBUTAMOL **TERBUTALINE**

SalAir® **Ventolin®** **Bricanyl®**



100 mcg 250 mcg

Aerosol inhaler Turbuhaler®

Short-Acting Muscarinic Antagonists (SAMA)

IPRATROPIUM

Atrovent®




20 mcg

Aerosol inhaler

Combination SABA + SAMA

SALBUTAMOL + IPRATROPIUM

Duolin HFA®




100 mcg/20 mcg

Aerosol inhaler

Inhaled Corticosteroids (ICS)

FLUTICASONE propionate

Flixotide®



50 mcg 125 mcg 250 mcg 50 mcg 100 mcg 250 mcg

Aerosol inhaler Accuhaler®

BUDESONIDE

Pulmicort®



100 mcg 200 mcg 400 mcg

Turbuhaler®

BECLOMETHASONE dipropionate

Beclazone® **Qvar® (ultrafine particle)**



50 mcg 100 mcg 250 mcg 50 mcg 100 mcg

Aerosol inhalers

Note: Beclazone® and Qvar® are not dose equivalent and are not interchangeable.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

BUDESONIDE + FORMOTEROL

Symbicort® **DuoResp Spiromax®** **Vannair®**



100/6 200/6 400/12* 200/6 400/12* 100/6 200/6

Turbuhaler® Dry powder inhaler Aerosol inhaler


*Symbicort 400/12 and DuoResp Spiromax 400/12 only funded if no more than 2 doses per day

Note: Symbicort 100/6, 200/6 and DuoResp Spiromax 200/6 are currently approved for Anti-Inflammatory Reliever (AIR) therapy. Vannair 100/6 and 200/6 is approved for maintenance use, but its use in AIR therapy is an unapproved indication.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Beta2 Agonists (LABA)

FLUTICASONE propionate + SALMETEROL

Seretide®




50/25 125/25 250/25 100/50* 250/50*

Aerosol inhaler Accuhaler®

*100/50 and 250/50 accuhaler only funded if no more than 2 doses per day

FLUTICASONE furoate + VILANTEROL

Breo Ellipta®




100/25 200/25

Dry powder inhaler

Long-Acting Beta2 Agonists (LABA)

SALMETEROL **FORMOTEROL (eformoterol)** **INDACATEROL**

Serevent® **Oxis®** **Onbrez Breezhaler®**




25 mcg 50 mcg 6 mcg 150 mcg 300 mcg

Aerosol inhaler Accuhaler® Turbuhaler® Breezhaler®

Long-Acting Muscarinic Antagonists (LAMA)

TIOTROPIUM **UMECLIDINIUM** **GLYCOPYRRONIUM**

Spiriva® **Spiriva Respimat®** **Incruse Ellipta®** **Seebri® Breezhaler®**



18 mcg 2.5 mcg 62.5 mcg 50 mcg


Handihaler® Fine mist inhaler Dry powder inhaler Breezhaler®

Funded by endorsement: LAMA inhaler is subsidised only for patients who have been diagnosed as having COPD using spirometry if spirometry is possible, and the prescription is endorsed accordingly (i.e. COPD documented as indication on prescription). Not subsidised if patient is also receiving treatment with another subsidised LAMA.

Combination Long-Acting Muscarinic Antagonists (LAMA) + Long-Acting Beta2 Agonists (LABA)

TIOTROPIUM + OLODATEROL **UMECLIDINIUM + VILANTEROL** **GLYCOPYRRONIUM + INDACATEROL**

Spolto Respimat® **Anoro Ellipta®** **Ultibro® Breezhaler®**



2.5 mcg/2.5 mcg 62.5 mcg/25 mcg 50 mcg/110 mcg


Fine mist inhaler Dry powder inhaler Breezhaler®

Funded via Special Authority: LAMA + LABA inhaler is subsidised only for patients who have been stabilised on a LAMA and the prescriber considers that the patient would receive additional benefit from switching to a combination product. Not subsidised if patient is also receiving treatment with a combination ICS and LABA.

Combination Inhaled Corticosteroids (ICS) + Long-Acting Muscarinic Antagonist (LAMA) + Long-Acting Beta2 Agonist (LABA)

FLUTICASONE furoate + UMECLIDINIUM + VILANTEROL **BUDESONIDE + GLYCOPYRRONIUM + FORMOTEROL**

Trelegy Ellipta® **Breztri Aerosphere®**



100 mcg/62.5 mcg/25 mcg 160 mcg/7.2 mcg/5 mcg

Dry powder inhaler Aerosol inhaler

Funded via Special Authority: ICS + LAMA + LABA 'triple therapy' inhaler is subsidised only for patients with a diagnosis of COPD confirmed by spirometry, or spirometry has been attempted and technically acceptable results are not possible and the patient is currently on an ICS/LABA or a LAMA/LABA, and meets the following clinical criteria:

- Patient has a COPD Assessment Test (CAT) score greater than 10, or
- Patient has had 2 or more exacerbations in the previous 12 months, or
- Patient has had one exacerbation requiring hospitalisation in the previous 12 months, or
- Patient has had an eosinophil count greater than or equal to 0.3×10^9 cells/L in the previous 12 months or the patient is currently receiving multiple inhaler triple therapy (ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to starting multiple inhaler triple therapy.

Spacers are available free to those who need them on a Practitioners Supply Order (PSO). Contact Manatū Hauora Ministry of Health for an order form on 0800 353 2425. Everyone should have an action plan. Find a range of management plans at asthmafoundation.org.nz

 **Funded**  **Not funded**  **Partially funded**

 **Funded by endorsement**  **Funded by Special Authority**

 **Low carbon footprint¹**  **High carbon footprint¹**

Funding information updated as of 1 June 2025.

Visit www.pharmac.govt.nz

DOWNLOAD AT:

asthmafoundation.org.nz